Clinical Trial Update: A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating SR58611A for relapse prevention in adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SR58611A

Snippet

Sponsor: Sanofi | Conditions: Depressive Disorder, Major Depression | Phase 3 | Status: COMPLETED